Compugen Advancing Cancer Immunotherapies to Clinical Trials

Compugen today said clinical trials will be launched for a pair of its cancer immunotherapy candidates targeting advanced solid tumors —its lead immuno-oncology program targeting PVRIG, which had been in clinical hold since April, and another program targeting the ILDR2, or immunoglobulin-like domain-containing receptor 2, protein whose development will be overseen by Bayer.Compugen said the FDA has lifted the clinical hold on PVRIG-targeting COM701 that the company disclosed on April 27,